Piboserod

Drug Profile

Piboserod

Alternative Names: 207266; SB 207266; SB 207266A

Latest Information Update: 20 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Serodus
  • Class Heart failure therapies; Indoles; Oxazines; Small molecules
  • Mechanism of Action Serotonin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Heart failure
  • Discontinued Atrial fibrillation; Irritable bowel syndrome

Most Recent Events

  • 18 Jun 2008 Efficacy and adverse events data from a phase II trial in Heart failure released by Bio-Medisinsk Innovasjon
  • 31 Jul 2007 Bio-Medisinsk Innovasjon completes a phase II trial in heart failure in Denmark, Norway, and the UK
  • 02 Nov 2005 Phase-II clinical trials in Heart failure in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top